Results 261 to 270 of about 2,232,804 (291)

Carcinoid Tumours and the Carcinoid Syndrome

1989
The purpose of this paper is to describe the clinical features, pathology and treatment of carcinoid tumours and the carcinoid syndrome. The content is based upon our personal experience of the management of the disorder and the original literature.
N. D. S. Bax, H. F. Woods, J. A. C. Thorpe, J. A. R. Smith   +3 more
openaire   +2 more sources

ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs).

, 2014
268 Background: Somatostatin analogs (SSAs) are the mainstay treatment for carcinoid syndrome. LAN is a long-acting SSA approved for this indication in >50 countries, but not yet in the US.
A. Vinik, E. Wolin, H. Audry, E. Gomez-Panzani   +3 more
semanticscholar   +1 more source

Complications of Midgut Carcinoid Tumors and Carcinoid Syndrome

Neuroendocrinology, 2004
The carcinoid syndrome, associated with carcinoid tumors of the midgut, consists of symptoms such as diarrhea, flushing, wheezing and cardiovascular symptoms. This review focuses on these symptoms and discusses therapeutic options. The symptoms are caused by the secretion of biogenic amines, polypeptides and other factors of which serotonin is the most
Ido P. Kema, Thera P. Links, Anouk N A van der Horst-Schrivers, Pax H.B. Willemse, A N Machteld Wymenga, Elisabeth G.E. de Vries   +5 more
openaire   +4 more sources

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

New England Journal of Medicine, 1986
We studied the effects of a long-acting analogue of somatostatin (SMS 201-995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome.
L. Kvols, C. Moertel, M. O’connell, A. Schutt, J. Rubin, R. Hahn   +5 more
semanticscholar   +1 more source

Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications

Reviews in Endocrine & Metabolic Disorders, 2020
G. Fanciulli, R. Ruggeri, E. Grossrubatscher, F. L. Calzo, T. D. Wood, A. Faggiano, A. Isidori, A. Colao, on behalf of Nike   +8 more
semanticscholar   +1 more source

Chemotherapy for the carcinoid syndrome

Cancer Chemotherapy and Pharmacology, 1981
Patients with carcinoid syndrome usually die from carcinomatosis, rather than the pharmacological effects of the tumour. Functioning carcinoid tumours are resistant to radiotherapy. Twenty-four different cytotoxic drugs or combinations have been used to treat the carcinoid syndrome, but only actinomycin D, cyclophosphamide, 5-fluorouracil, melphalan ...
openaire   +3 more sources

Carcinoids and carcinoid syndrome

The American Journal of Medicine, 1987
Werner Creutzfeldt, F. Stöckmann
openaire   +3 more sources

The carcinoid syndrome

Irish Journal of Medical Science, 1967
Michael A. Moloney, J. Leahy
openaire   +3 more sources

Management of Carcinoid Syndrome

Archives of Surgery, 1965
IT HAS BEEN little more than 75 years since carcinoid was first recognized1,2,3and prior to 1939 no case of carcinoid was properly diagnosed preoperatively.4During the past five years increasing information has resulted in frequent recognition and successful treatment of this malignant tumor.
openaire   +3 more sources

Carcinoid Syndrome

AJN, American Journal of Nursing, 1980
openaire   +4 more sources